Obstet Gynecol:ACOG提倡使用双重抗生素治疗淋病

2015-10-25 Seven L 译 MedSci原创

淋球菌对磺酰胺类、四环素、青霉素耐药,因为头孢曲松钠和阿奇霉素是一线治疗药物。在美国淋病是第二个最常见的细菌性性传播疾病,每年估计有 820,000 例新发案例。在2007年,因为淋球菌对氟喹诺酮耐药,疾控中心对淋病的治疗停止推荐氟喹诺酮,使得头孢菌素成为仅存的推荐的抗生素种类。抗生素耐药性产生后会导致治疗的失败、并发症风险增加,以及促进疾病的性传播。ACOG建议头孢曲松钠和阿奇霉素同时使用。对宫

淋球菌对磺酰胺类、四环素、青霉素耐药,因为头孢曲松钠和阿奇霉素是一线治疗药物。

在美国淋病是第二个最常见的细菌性性传播疾病,每年估计有 820,000 例新发案例。在2007年,因为淋球菌对氟喹诺酮耐药,疾控中心对淋病的治疗停止推荐氟喹诺酮,使得头孢菌素成为仅存的推荐的抗生素种类。

抗生素耐药性产生后会导致治疗的失败、并发症风险增加,以及促进疾病的性传播。

ACOG建议头孢曲松钠和阿奇霉素同时使用。对宫颈、尿道、直肠没有并发症的淋病首选的一线治疗方案是肌注头孢曲松钠 250 mg+ 口服阿奇霉素1 g。二线方案包括口服头孢克肟+口服阿奇霉素,为预防严重的青霉素过敏,可口服吉米沙星+阿奇霉素或肌注庆大霉素+阿奇霉素。

对于感染的妊娠期女性也需要双重治疗,不过不需要进行治疗测试,他们只需要在孕晚期进行再次检查,除非她们最近一直在治疗。

对使用一二线方案治疗的泌尿系或直肠没有并发症的淋病也不需要进行治疗测试。

在治疗前几个月反复感染的患者,需要在治疗后3个月复查相关检查。作者提到:对于复查仍是阳性结果的患者,很有可能是再感染而不是治疗失败。

ACOG还有其他推荐:


伴有咽淋病的女性替代方案治疗后14天需要通过培养或核酸检测疗效。
60天内患者的性伴侣需要对淋球菌和沙眼衣原体感染进行评估和治疗。
患者和性伴侣在治疗后7天内不能进行性活动,必须要性伴侣得到充分的治疗后。

原始出处:

Committee Opinion No. 645 Summary: Dual Therapy for Gonococcal Infections.Obstet Gynecol. 2015;126:1126.

Medscape:ACOG Advocates Dual Therapy for Gonococcal Infections.Medscape.Oct 22,2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011206, encodeId=61a6201120636, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 25 19:17:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043870, encodeId=e4fe20438e077, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jul 03 11:17:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345192, encodeId=dda1134519229, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581212, encodeId=bddf15812124a, content=<a href='/topic/show?id=4995186984' target=_blank style='color:#2F92EE;'>#ACOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1869, encryptionId=4995186984, topicName=ACOG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-25 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011206, encodeId=61a6201120636, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 25 19:17:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043870, encodeId=e4fe20438e077, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jul 03 11:17:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345192, encodeId=dda1134519229, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581212, encodeId=bddf15812124a, content=<a href='/topic/show?id=4995186984' target=_blank style='color:#2F92EE;'>#ACOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1869, encryptionId=4995186984, topicName=ACOG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011206, encodeId=61a6201120636, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 25 19:17:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043870, encodeId=e4fe20438e077, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jul 03 11:17:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345192, encodeId=dda1134519229, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581212, encodeId=bddf15812124a, content=<a href='/topic/show?id=4995186984' target=_blank style='color:#2F92EE;'>#ACOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1869, encryptionId=4995186984, topicName=ACOG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011206, encodeId=61a6201120636, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Oct 25 19:17:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043870, encodeId=e4fe20438e077, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jul 03 11:17:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345192, encodeId=dda1134519229, content=<a href='/topic/show?id=cd305543152' target=_blank style='color:#2F92EE;'>#抗生素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55431, encryptionId=cd305543152, topicName=抗生素治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581212, encodeId=bddf15812124a, content=<a href='/topic/show?id=4995186984' target=_blank style='color:#2F92EE;'>#ACOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1869, encryptionId=4995186984, topicName=ACOG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Tue Oct 27 06:17:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-27 仁心济世

相关资讯

新型耐药淋球菌菌株H041或致淋病无药可治

 在近日召开的第19届国际性病研究协会(ISSTDR)大会上,瑞典学者M Unemo报告了一种新型耐药淋球菌菌株H041。这种新型淋球菌菌株对广谱头孢菌素头孢曲松耐药,而头孢曲松是淋病经验治疗的最后选择,这意味着淋病无药可治的时代可能来临。相关报告发表于《性传播感染》期刊上(Sex Transm Infect 2011;87:A76)。   M Unemo等研究人员使用7种验证试验对H041进